Please describe your background and patient setting

How many patients with cardiomyopathy do you manage? What % have ATTR cardiomyopathy?

What is your current treatment algorithm for ATTR CM patients?

What are your overall thoughts on the results from the Attribute-CM Phase B study?

Where would you see acoramidis fitting into your management of patients if approved?

Although we have limited data at this time, do you see any weaknesses of acoramidis vs tafamdis or any of the upcoming silencers?

Do you see acoramidis as differentiated & superior to tafamidis or  not?  Recognizing the difficculties of cross-trial comparisons (which are particulalry acute here given how different placebo compared), do you think the performance that BBIO showed on mortality & CV hospitalizations is meaningfully superior to tafamidis?  What about the performance on biomarkets and also the data they provided on acoramidis vs. tafamidis based on the tafamidis drop-ins in the trial?    

What do you think about the safety / side-effect profile of acoramidis and how does that compare to tafamidis?  Any advantage or disadvantage there?

Some have metnioned that acoramidis and tafamidis will be huge beneficiaries of the Inflation Reduction Act.  There is a provision in there that takes the donut hole from $14K down to $2K.  Some have suggested this could double the market opportunity for this drug class as it becomes affordable for a lot more people.  What do you think about this notion?